COVID Updates

As the coVID-19 situation continues to evolve, we will keep up-to-date information on our website.


Updates for faculty, staff and students, click here

For general resources, click here. 



For media enquiries or more information about research at the Djavad Mowafaghian Centre for Brain Health, please contact Vanessa Hrvatin, Communications Coordinator.

To keep in touch with the Centre and up-to-date on our research, follow us on Twitter or subscribe to Brain Matters, our monthly e-newsletter.

Light therapy treatment is effective for depression, researchers say.
Researchers find light therapy effective for depression Nov 18, 2015

New research finds that light therapy can treat non-seasonal depression and improve the overall wellbeing of people suffering from the disease.

HeadsUpGuys helps men seek mental wellness on their own terms Oct 20, 2015

Whether they’re conscious of it or not, many men struggle to identify and seek help for symptoms of depression. HeadsUpGuys – an online tool developed by Dr. John Ogrodniczuk and his team of clinicians, researchers, and mental health advocates – was designed to support men on their terms.

Jenna Smith-Forrester
Trainee profile: Jenna Smith-Forrester Oct 9, 2015

“Ultimately, I hope to help unleash the potential in students in healthcare-related programs to serve as change agents. Together we can usher in an era of unparalleled service delivery, while reducing errors, waste, and cost,” she says. “One day I will find my niche, or perhaps I shall create it.”

Dr. Raymond Lam receives CPA award for clinical research excellence Oct 5, 2015

The Canadian Psychiatric Association (CPA) recognized exceptional psychiatrists, psychiatric residents and individuals for their contributions to the mental health of Canadians during their annual meeting in Vancouver on October 2. 

Early findings in rTMS trial give hope to people with depression Oct 2, 2015

A research study that hopes to improve the convenience and reduce the cost of a Health Canada-approved treatment for depression is underway, and the preliminary results are encouraging. Dr. Fidel Vila-Rodriguez, director of the Non-Invasive Neurostimulation Therapies (NINET) Lab at the Djavad Mowafaghian Centre for Brain Health, presented twice on his work at the Canadian Psychiatric Association Annual Meeting in Vancouver on October 1, 2015.

UBC funds Heart and Stroke partnership
UBC and Heart & Stroke Foundation partner to fast-track research Sep 17, 2015

UBC’s investment of $1.5 million over three years in the Heart and Stroke Foundation Canadian Partnership for Stroke Recovery will accelerate the development of new therapies for people living with stroke disability.

Man receives MS drug infusion at Djavad Mowafaghian Centre for Brain Health
Analysis of data over 18 years demonstrates high incidence, increasing prevalence of MS in BC Aug 14, 2015

The number of people living with multiple sclerosis (MS) in British Columbia has increased over the past 18 years, but the number of new MS cases each year has held stable, a new study has found.

Alcohol and smoking associated with anxiety and depression in multiple sclerosis Aug 13, 2015

Researchers hope the results of a new study will aid doctors in better supporting patients with multiple sclerosis. The study, published this week in Multiple Sclerosis Journal, tracked over 900 patients from four Canadian provinces over two years and found that during this time more than 50 percent were anxious, and over 35 percent were depressed.

Dr. Christian Naus
New research: Target healthy cells to stop brain cancer “hijack” Aug 12, 2015

New research into brain cancer suggests treatments should target the cells around a tumor to stop it from spreading.

UBC research team Christian Naus (pictured), Wun Chey Sin and John Bechberger study glioma, the most aggressive form of adult brain cancer. Glioma has a median survival rate of about 15 months and two-year survival rate of 30 per cent because it is difficult to completely remove cancer cells without compromising brain functions and chemotherapy and radiotherapy do not prevent the regrowth of remaining cancer cells.

Researchers develop test to measure effectiveness of treatments for Huntington’s disease Aug 7, 2015

A new test developed by UBC researchers allows physicians to measure the effects of gene silencing therapy in Huntington’s disease and will support the first human clinical trial of a drug that targets the genetic cause of the disease.

The gene silencing therapy being tested aims to reduce the levels of a toxic protein in the brain that causes Huntington’s disease.